Chronic Wounds : 1 Diabetic Foot Ulcers | 2 Leg ulcers

1 Kontopodis, N., et al. | 2 Rainys, D., et al.

Diabetic Foot Ulcers (DFU)

Effectiveness of RegenPRP® fibrin clot to enhance healing of DFU in patients with concomitant peripheral arterial disease (PAD) and critical limb ischemia5.

Study on 72 patients divided into two groups based on the severity of PAD according to the Fountain classification.

RESULTS AT 16 WEEKS

Group A, stage I, IIa and IIb

42 patients without critical limb ischemia

  • 86 % of ulcer area reduction of > 50 %
  • 83 % of ulcer area reduction of > 90%
  • 100 % of limb salvage

Group B, stage III and IV

30 patients with Critical Limb Ischemia

  • 73 % of ulcer area reduction of > 50 %
  • 56 % of ulcer area reduction of > 90%
  • 73 % of limb salvage

Leg ulcers of vascular origin and other aetiologies

Effectiveness of RegenPRP® gel in the treatment of hard-to heal leg ulcers6.

Study on 69 patients (35 in the autologous PRP group and 34 in the control group).

RegenPRP® gel showed superiority over conventional treatment in wound bed coverage with granulation tissue formation. At 8 weeks wound size reduction in the RegenPRP® gel group was 52.35% and 33.36% in the control group.

Chronic ulcer on the lower limb with exposed tendons in a 83 year old woman.

REFERENCE

Kontopodis, , et al. Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients With Concomitant Peripheral Arterial Disease and Critical Limb Ischemia. The international journal of lower extremity wounds 15, 45-51 (2016).

Rainys, , et al., Effectiveness of autologous platelet-rich plasma gel in the treatment of hard-to-heal leg ulcers: a randomised control trial. J Wound Care, 2019. 28(10): p. 658-667.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.